OBJECTIVE: Multiparametric MRI (mp-MRI) of the prostate is increasingly being used for local staging and detection of recurrence of prostate cancer (PCA). In patients with elevated prostate-specific antigen (PSA), mp-MRI could provide information on the position of the cancer, allowing adjustments to be made to the needle depth and direction before repeat transrectal ultrasound (TRUS)-guided biopsy to ensure accurate sampling of lesions. The purpose of the prospective study was to evaluate mp-MRI of the prostate in patients with PSA elevation before initial TRUS-guided biopsy. METHODS: mp-MRI was performed in 94 patients using a 1.5-T scanner (MAGNETOM Aera(®); Siemens Healthcare, Erlangen, Germany) and 16-channel phased-array body coil (Siemens Healthcare). T2 weighted images (T2WI), diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) MRI and MR spectroscopy were obtained. TRUS-guided random biopsies and additional targeted biopsies of suspicious MRI areas were performed. RESULTS: Additional targeted biopsies were obtained in 17 of 43 (40%) patients with PCA. 11 of 17 targeted biopsies contained PCA. 5 of 11 PCAs were diagnosed only by additional targeted biopsies. Sensitivity of mp-MRI in patients was 97.7% and specificity was 11.8%. mp-MRI was false negative in one patient. Sensitivity of mp-MRI in 207 lesions was 80.9% and specificity was 44.7%. In a logistic regression model, the apparent diffusion coefficient value was the only significant parameter to differentiate malignant and benign lesions. CONCLUSION: mp-MRI should be performed in patients with PSA elevation before initial TRUS-guided biopsy to allow additional targeted biopsies from suspicious areas of MRI. We recommend mp-MRI with T2WI, DWI, DCE MRI and MR spectroscopy. DWI as the most reliable technique should be used in every mp-MRI. ADVANCES IN KNOWLEDGE: DWI is the most reliable technique in mp-MRI of the prostate.
OBJECTIVE: Multiparametric MRI (mp-MRI) of the prostate is increasingly being used for local staging and detection of recurrence of prostate cancer (PCA). In patients with elevated prostate-specific antigen (PSA), mp-MRI could provide information on the position of the cancer, allowing adjustments to be made to the needle depth and direction before repeat transrectal ultrasound (TRUS)-guided biopsy to ensure accurate sampling of lesions. The purpose of the prospective study was to evaluate mp-MRI of the prostate in patients with PSA elevation before initial TRUS-guided biopsy. METHODS: mp-MRI was performed in 94 patients using a 1.5-T scanner (MAGNETOM Aera(®); Siemens Healthcare, Erlangen, Germany) and 16-channel phased-array body coil (Siemens Healthcare). T2 weighted images (T2WI), diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) MRI and MR spectroscopy were obtained. TRUS-guided random biopsies and additional targeted biopsies of suspicious MRI areas were performed. RESULTS: Additional targeted biopsies were obtained in 17 of 43 (40%) patients with PCA. 11 of 17 targeted biopsies contained PCA. 5 of 11 PCAs were diagnosed only by additional targeted biopsies. Sensitivity of mp-MRI in patients was 97.7% and specificity was 11.8%. mp-MRI was false negative in one patient. Sensitivity of mp-MRI in 207 lesions was 80.9% and specificity was 44.7%. In a logistic regression model, the apparent diffusion coefficient value was the only significant parameter to differentiate malignant and benign lesions. CONCLUSION: mp-MRI should be performed in patients with PSA elevation before initial TRUS-guided biopsy to allow additional targeted biopsies from suspicious areas of MRI. We recommend mp-MRI with T2WI, DWI, DCE MRI and MR spectroscopy. DWI as the most reliable technique should be used in every mp-MRI. ADVANCES IN KNOWLEDGE: DWI is the most reliable technique in mp-MRI of the prostate.
Authors: Axel Wetter; Tobias A Engl; Darius Nadjmabadi; Klaus Fliessbach; Thomas Lehnert; Jessen Gurung; Wolf-Dietrich Beecken; Thomas J Vogl Journal: AJR Am J Roentgenol Date: 2006-09 Impact factor: 3.959
Authors: Thomas Hambrock; Diederik M Somford; Caroline Hoeks; Stefan A W Bouwense; Henkjan Huisman; Derya Yakar; Inge M van Oort; J Alfred Witjes; Jurgen J Fütterer; Jelle O Barentsz Journal: J Urol Date: 2009-12-14 Impact factor: 7.450
Authors: Amita Shukla-Dave; Hedvig Hricak; Steven C Eberhardt; Semra Olgac; Manickam Muruganandham; Peter T Scardino; Victor E Reuter; Jason A Koutcher; Kristen L Zakian Journal: Radiology Date: 2004-06 Impact factor: 11.105
Authors: Tom W J Scheenen; Stijn W T P J Heijmink; Stefan A Roell; Christina A Hulsbergen-Van de Kaa; Ben C Knipscheer; J Alfred Witjes; Jelle O Barentsz; Arend Heerschap Journal: Radiology Date: 2007-09-11 Impact factor: 11.105
Authors: Liang Zhen; Xiaoqiang Liu; Chen Yegang; Yang Yongjiao; Xu Yawei; Kang Jiaqi; Wang Xianhao; Song Yuxuan; Hu Rui; Zhang Wei; Ou Ningjing Journal: BMC Cancer Date: 2019-12-23 Impact factor: 4.430